Loading
Life sciences · Journal article
Febs Letters · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Acquired resistance to vemurafenib, a BRAF V600E ‐targeted therapy, remains a major challenge in melanoma. The translation initiation factor eIF6 has been implicated in cancer; however, its role in vemurafenib resistance is poorly understood. We investigated eIF6 using melanoma cell lines with distinct mutational backgrounds. RNA sequencing of a resistant cell line revealed dysregulation of MAPK, PI3K‐AKT, metabolic, and ribosome biogenesis pathways together with increased eIF6 expression and alterations in translation‐related signaling. Silencing of eIF6 led to reduced proliferation and partially restored vemurafenib sensitivity, while its overexpression increased sensitivity irrespective of BRAF status via mTOR and MAPK modulation. These findings reveal a context‐dependent role for eIF6, linking translation regulation to therapeutic response in melanoma.